{"id":974196,"date":"2026-06-22T08:19:08","date_gmt":"2026-06-22T12:19:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/"},"modified":"2026-06-22T08:19:08","modified_gmt":"2026-06-22T12:19:08","slug":"clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/","title":{"rendered":"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial"},"content":{"rendered":"
\n

Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I\/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).<\/p>\n

All 24 participants across Cohorts 1 through 4 have successfully completed treatment according to the study protocol.<\/p>\n

The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in Alcohol Use Disorder patients.<\/p>\n

“We are pleased to have successfully completed treatment for all participants in Part A of the study, fully aligned with the clinical protocol,\u201d said Adi Zuloff\u2011Shani, PhD, CEO of Clearmind Medicine. \u201cThis achievement reflects the dedication of our clinical teams and the value of our partnerships with world\u2011class research centers across the United States and Israel. With data review now underway, we are eager to progress to the next phase of development and continue advancing CMND\u2011100 as a promising therapeutic candidate for Alcohol Use Disorder.”<\/p>\n

The multicenter trial is being conducted under FDA oversight (at leading sites in the United States and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.<\/p>\n

\n About\u00a0Clearmind\u00a0Medicine Inc.<\/b>\n <\/p>\n

Clearmind is a clinical-stage\u00a0neuroplastogens\u00a0pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation,\u00a0neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.<\/p>\n

The Company\u2019s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.<\/p>\n

Shares of Clearmind are listed for trading on Nasdaq under the symbol\u00a0\u201cCMND.\u201d<\/p>\n

For further information, visit:\u00a0https:\/\/www.clearmindmedicine.com<\/u><\/a>\u00a0or contact:<\/p>\n

Investor Relations
invest@clearmindmedicine.com<\/u><\/a>
www.Clearmindmedicine.com<\/u><\/a><\/p>\n

\n Forward-Looking Statements:<\/b>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses\u00a0the timing and progress of its clinical trial, how the Company is currently assessing the dataset and, assuming results remain favorable, its intension to initiate the next stage of the clinical program in Alcohol Use Disorder patients, progressing to the next phase of development and continuing to advance CMND\u2011100 as a promising therapeutic candidate for Alcohol Use Disorder.\u00a0Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.\u00a0Such expectations, beliefs and projections are expressed in good faith.\u00a0However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is\u00a0made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission (\u201cSEC\u201d), including, but not limited to, the risks detailed in the Company\u2019s annual report on Form 20-F for the fiscal year ended October 31,\u00a02025\u00a0and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I\/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). All 24 participants across Cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in Alcohol Use Disorder patients. “We are pleased to have successfully … <\/p>\n

Continue reading “Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-974196","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nClearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I\/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). All 24 participants across Cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in Alcohol Use Disorder patients. “We are pleased to have successfully … Continue reading "Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T12:19:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\\\/II Trial\",\"datePublished\":\"2026-06-22T12:19:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/\"},\"wordCount\":768,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/\",\"name\":\"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\\\/II Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==\",\"datePublished\":\"2026-06-22T12:19:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\\\/II Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/","og_locale":"en_US","og_type":"article","og_title":"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial - Market Newsdesk","og_description":"Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I\/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). All 24 participants across Cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in Alcohol Use Disorder patients. “We are pleased to have successfully … Continue reading \"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-22T12:19:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial","datePublished":"2026-06-22T12:19:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/"},"wordCount":768,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/","name":"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==","datePublished":"2026-06-22T12:19:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1MDMyNCM3NjcxNTg5IzUwMDA4NjkzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reaches-major-milestone-completing-part-a-treatment-in-fda-regulated-phase-i-ii-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA\u2011Regulated Phase I\/II Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/974196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=974196"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/974196\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=974196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=974196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=974196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}